search button
Open Access

Efficacy and safety of PD‑1/PD‑L1 inhibitors combined
with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis

  • Authors:
    • Shiqing Su

  • View Affiliations

  • Published online on: July 17, 2023     https://doi.org/10.3892/ol.2023.13960
  • Article Number: 373

  • Copyright: © Su . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although the efficacy and safety of programmed cell death 1 (PD‑1)/programmed cell death ligand 1 (PD‑L1) inhibitor combined with chemotherapy vs. chemotherapy alone has been analyzed, there have been no in‑depth studies on the outcomes of patients with PD‑L1 positive advanced gastric or gastro‑esophageal junction cancer patients (GC/GEJC). This systematic review and meta‑analysis focused on comparing the efficacy and safety of PD‑1/PD‑L1 inhibitors vs. PD‑1/PD‑L1 inhibitors combined with chemotherapy vs. chemotherapy in PD‑L1 positive advanced GC/GEJC patients, aiming to provide more precise guidance for the clinical treatment of GC/GEJC. In this meta‑analysis, PubMed, Embase, and Cochrane Library were searched from the establishment of the database till June 2022. Randomized controlled trials (RCTs) in which control patients underwent chemotherapy and experimental group patients underwent PD‑1/PD‑L1 inhibitors or PD‑1/PD‑L1 inhibitors combined with chemotherapy were included in this investigation. Investigations without complete information, studies from which information could not be extracted, duplicate articles, animal studies, review articles, and systematic reviews were excluded. The pooled results suggested that chemotherapy combined with immunotherapy prolonged overall survival (OS) in patients with advanced GC/GEJC, while progression free‑survival (PFS) with PD‑1/PD‑L1 inhibitors alone or in combination with chemotherapy were all improved compared with chemotherapy alone. However, PD‑1/PD‑L1 inhibitors did not significantly increase objective response rates (ORR) in PD‑L1‑positive patients compared with chemotherapy, but in combination with chemotherapy, they did improve ORR. The pooled results also showed that patients treated with PD‑1/PD‑L1 inhibitors had higher stable disease (SD) and progressive disease (PD) rates compared to chemotherapy in PD‑L1‑positive patients. Additionally, in PD‑L1‑positive patients, PD‑1/PD‑L1 inhibitors alone or combined with chemotherapy increased OS compared with chemotherapy alone. However, PD‑1/PD‑L1 inhibitors only prolonged PFS compared with chemotherapy alone in patients with a combined positive score (CPS; 100% of cells were required to be positively stained) for PD‑L1, but when combined with chemotherapy, OS and PFS were prolonged in all PD‑L1‑positive patients compared with chemotherapy alone. Finally, the pooled results showed that the incidence of adverse events of PD‑1/PD‑L1 inhibitors in PD‑L1‑zpositive patients was significantly lower than that in patients treated with chemotherapy alone. In conclusion, single agent of PD‑1/PD‑L1 inhibitor alone or combined with chemotherapy significantly prolongs the survival of patients compared with chemotherapy alone, with fewer adverse effects. However, the degree of CPS may affect efficacy, thus further investigation is required.
View Figures
View References

Related Articles

Journal Cover

September-2023
Volume 26 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Su S: Efficacy and safety of PD‑1/PD‑L1 inhibitors combined <br />with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis. Oncol Lett 26: 373, 2023
APA
Su, S. (2023). Efficacy and safety of PD‑1/PD‑L1 inhibitors combined <br />with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis. Oncology Letters, 26, 373. https://doi.org/10.3892/ol.2023.13960
MLA
Su, S."Efficacy and safety of PD‑1/PD‑L1 inhibitors combined <br />with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis". Oncology Letters 26.3 (2023): 373.
Chicago
Su, S."Efficacy and safety of PD‑1/PD‑L1 inhibitors combined <br />with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis". Oncology Letters 26, no. 3 (2023): 373. https://doi.org/10.3892/ol.2023.13960